Rheumatology: 15. Osteoporosis

CMAJ. Canadian Medical Association Journal

Volumn 165, Issue 1, 2001, Pages 45-50

  Wade, J P ^a  

^a Mary Pack Arthritis Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM CARBONATE; CONJUGATED ESTROGEN; ESTRADERM PATCH; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL; ETIDRONIC ACID; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE ACETATE; PIPERAZINE ESTRONE SULFATE; PROGESTERONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG; VITAMIN D;

CALCIUM INTAKE; DIET; ESTROGEN THERAPY; FRACTURE; HUMAN; LIFESTYLE; OSTEOPOROSIS; REVIEW; RHEUMATOLOGY; RISK FACTOR; SMOKING; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0034920886     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. The prevention and treatment of osteoporosis
2. Prevention and management of osteoporosis: Consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada
3. Treatment of postmenopausal osteoporosis
4. Pre-existing fractures and bone mass predict vertebral fracture incidence in women
5. Current and projected rates of hip fracture in Canada
6. Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures
7. Prevalence of low femoral bone density in older US women from NHANES III
8. Optimal calcium intake
9. 3 and calcium to prevent hip fractures in elderly women
10. Hip fracture and the use of estrogens in postmenopausal women
11. The effects of calcium supplementation (milk powder or tablets) and exercise on bone density in postmenopausal women
12. Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment
13. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium
14. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women
15. Estrogen replacement therapy and fractures in older women
16. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer
17. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer
18. Molecular basis of agonism and antagonism in the oestrogen receptor
19. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial
20. The effects of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial
21. Intranasal salmon calcitonin for the prevention and treatment of postmenopausal osteoporosis
22. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study
23. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures
24. Use of calcitonin in the treatment of bone pain associated with osteoporosis
25. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis
26. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
27. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures
28. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age
29. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial